Quantum-Si (NASDAQ:QSI) Releases Quarterly Earnings Results, Meets Expectations

Quantum-Si (NASDAQ:QSI) announced its quarterly earnings results on Thursday. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11), FiscalAI reports. Quantum-Si had a negative return on equity of 47.35% and a negative net margin of 5,605.88%.The business had revenue of $0.34 million for the quarter, compared to analyst estimates of $0.30 million.

Here are the key takeaways from Quantum-Si’s conference call:

• Proteus launch delayed from the end of 2026 to the second quarter of 2027 as Quantum-Si adds an integrated instrument design cycle to improve repeatability, manufacturing yields, and product readiness.
• Management remains confident in the underlying sequencing technology and expects the additional development time could support launch detection of 19 or 20 amino acids, up from the previously planned 18.
• The company cited substantial market potential, including more than $4 billion annually in non-human proteomics and opportunities such as AAV serotyping, pathogen surveillance, and agricultural research; it has qualified more than 250 institutions interested in Proteus.
• Quantum-Si announced a targeted workforce reduction of approximately 20%, expected to generate about $12 million in annual operating expense savings and extend its cash runway into the fourth quarter of 2028.
• Second-quarter revenue fell to $344,000 from $591,000 a year earlier, while first-half revenue declined to $602,000 from $1.4 million; the company reiterated full-year 2026 revenue guidance of approximately $1 million.

Quantum-Si Trading Down 5.7%

Shares of QSI opened at $0.79 on Friday. Quantum-Si has a 12-month low of $0.69 and a 12-month high of $3.10. The stock has a market cap of $172.03 million, a P/E ratio of -1.55 and a beta of 3.24. The company has a 50-day moving average of $0.87 and a two-hundred day moving average of $0.93.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Prudential Financial Inc. purchased a new stake in Quantum-Si in the 2nd quarter valued at approximately $25,000. Cerity Partners LLC purchased a new position in Quantum-Si during the second quarter worth $29,000. Dimensional Fund Advisors LP purchased a new position in Quantum-Si during the fourth quarter worth $34,000. BNP Paribas Financial Markets increased its position in Quantum-Si by 101.3% during the third quarter. BNP Paribas Financial Markets now owns 30,464 shares of the company’s stock worth $43,000 after buying an additional 15,331 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System acquired a new position in shares of Quantum-Si in the fourth quarter worth $45,000. 39.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Quantum-Si from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Quantum-Si has an average rating of “Reduce” and an average price target of $1.00.

Trending Headlines about Quantum-Si

Here are the key news stories impacting Quantum-Si this week:

• Positive Sentiment: Quantum-Si reported a second-quarter loss of $0.11 per share, better than the Zacks consensus estimate of a $0.13 loss and narrower than the $0.16 loss recorded a year earlier. Revenue of $0.34 million also exceeded the $0.30 million analyst estimate. Quantum-Si Q2 earnings report
• Positive Sentiment: Management said cost-reduction initiatives are expected to extend the company’s cash runway into the fourth quarter of 2028, reducing near-term financing risk. Quantum-Si also highlighted potential new market opportunities for protein sequencing. Quantum-Si second-quarter financial results and Proteus update
• Positive Sentiment: Options activity was unusually elevated, with investors purchasing 20,554 call options—more than 10 times typical volume—indicating increased speculative interest in QSI.
• Neutral Sentiment: Quantum-Si maintained fiscal 2026 revenue guidance of approximately $1.0 million, broadly matching the analyst consensus, providing little evidence of a near-term outlook upgrade.
• Negative Sentiment: The company expects the commercial launch of its Proteus platform in the second quarter of 2027, leaving investors reliant on a future product milestone. Quantum-Si’s revenue base remains extremely small, while its reported net margin was negative 5,605.88% and return on equity was negative 47.35%. Quantum-Si earnings report

About Quantum-Si

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.